Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-108 in Relapsed or Refractory B-cell Lymphoma
NCT04356846Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lacutoclax in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose, Recommended Phase Two Dose at 7 weeks, Number of subjects with adverse events and its frequency and 4 more. Status: unknown.
02
Drugs
lacutoclax
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04356846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356846.